|Required Preventive Service||Target Population||Recommendation||Coverage Clarifications||Effective Date of Coverage (plan year beginning on or after)|
|BRCA-Related Cancer: Risk Assessment, Genetic Counseling and Genetic Testing (USPSTF)||Women with a personal history or family history of breast, ovarian, tubal, or peritoneal cancer or ancestry associated with BRCA 1 and/or 2 gene mutation||Primary care clinicians should assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.||Federal FAQs, Set 12, Q6: genetic counseling and BRCA testing are covered without cost sharing. Set 26, Q1: recommendation applies to asymptomatic women, including women who previously had cancer unrelated to BRCA.||Coverage for 2019 recommendation will take effect 8/31/2020.
Current coverage policy for 2014 recommendation has been in place since 1/31/2015
|Breast Cancer Screening (HRSA)||Women ages 40 to 74 with average-risk for breast cancer||Screening mammography at least every 2 years and as frequently as once a year||12/31/2017|
|Breast Cancer Screening (USPSTF)||
Women age 50-74
Screening mammography every 2 years
|Breast Cancer: Medications for Risk Reduction (USPSTF)||Women age 35+ at increased risk||Clinicians should offer to prescribe risk reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effect.||Federal FAQs, Set 18, Q1: plans must cover preventive medications for eligible women with risk factors without cost-sharing.||Coverage for 2019 recommendation will take effect 9/30/2020
Current coverage policy for 2013 recommendation has been in place since December 31, 2014
|Cervical Cancer Screening (USPSTF)||Women age 21 – 65||Pap smear every 3 years for women 21 to 29. Pap smear every 3 years for women 30 to 65, or a high-risk HPV (hrHPV) test every 5 years, or a Pap smear in combination with a hrHPV test every 5 years.||Federal FAQs, Set 12, Q12: high-risk HPV DNA testing for women with normal Pap results should begin at age 30 and not be administered more than once every 3 years.||Coverage for the 2018 recommendation will take effect 8/31/2019. Current coverage policy for the 2012 recommendation has been in place since 3/31/2013|
|Cervical Cancer Screening: Human Papillomavirus Testing (HRSA)||Women age 30+||HPV test with Pap test in women with prior normal Pap results, beginning at age 30 and occurring no more frequently than every 3 years.||Federal FAQs, Set 12, Q12: high-risk HPV DNA testing for women with normal Pap results should begin at age 30 and not be administered more than once every 3 years.||8/1/2012|
|Colorectal Cancer Screening (USPSTF)||Adults age 50 – 75||
||Federal FAQs, Set 12, Q5: insurers cannot impose cost-sharing for polyp removal when screening colonoscopy performed. Set 26 Q7: cannot charge cost sharing for anesthesia that clinician has deemed medically appropriate for a preventive colonoscopy.||6/30/2017|
|Lung Cancer Screening (USPSTF)||Adults age 55 – 80 with history of smoking||Annual low-dose computed tomography (LDCT) in adults age 55 – 80 with a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. For those who smoke, tobacco cessation counseling is recommended.||None||12/31/2014|
|Skin Cancer Prevention: Behavioral Counseling||Children, parents of young children, adolescents and young adults (persons aged 6 months to 24 years) with fair skin type||Counsel about minimizing exposure to UV radiation to reduce their risk of skin cancer||The 2018 recommendation updates the 2012 recommendation, which limited the age range of the target population to individuals 10 to 24 years old.||
Coverage for the 2018 recommendation will take effect 3/31/2019.
Current coverage policy for the 2012 recommendation in place since 7/31/2013.